Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in developed countries and is associated with increasing obesity and type II diabetes incidence. A risk of cardiovascular complications comes with steatosis as such while cirrhosis risk development is associated with steatohepatitis as a more advanced disease stage.
All reasons of progression of steatosis to steatohepatitis haven't been discovered yet. NAFLD diagnosis is based on liver biopsy but non-invasive transient elastography has increasing importance in fibrosis staging.
Treatment is based on life-style modification. As it comes from definition, NAFLD does not have a relation to alcohol consumption, but in some cases the hidden consumption could play a role and should be excluded.
Many new molecules in treatment are being tested but no targeted pharmacotherapy is available at present.